Fundraising FoxVenrock — 2026 Investments
10 investments dated 2026 · listed companies and verified rows first · show all
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateBraidwellCommodore CapitalJanus Henderson InvestorsOrbiMed+2 more
Arca Wealth is a registered investment adviser providing financial planning and wealth management services, including expertise in stock options and ESPP management for high-income professionals and business owners.
FintechBethesda, US
Rron Rexha(Founder)in
Co-investorsGeneral CatalystIndex Ventures
.png)
Arca develops industrial carbon mineralization technology that accelerates reactions between CO₂ and alkaline rocks and industrial byproducts to permanently store carbon, generating carbon credits.
CleantechClimate TechDeep Tech
Bethany Ladd(Founder)inGreg Dipple(Founder)Peter Scheuermann(Founder)Rron Rexha(Founder)
Co-investorsLowercarbon CapitalRobin CapitalAntlerDraper B1Enzo VenturesGeneral Catalyst+2 more
Encoded develops gene therapies for neurological disorders through an integrated platform approach.
BiotechSouth San Francisco, US
Stephanie Tagliatela(Founder)inKartik Ramamoorthi, Ph.D.(Co-founder, Chief Executive Officer & Board Member)Kartik Ramamoorthi(Founder)
Co-investorsARCH Venture PartnersBioBritGV (Google Ventures)Illumina VenturesMenlo VenturesSoftBank Vision Fund+6 more
Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's.
BiotechDeep TechHealthtechWaltham, US
Mark Vignola(Chief Financial Officer)inJonathan Violin(President)in
Co-investorsSanofi VenturesTCG CrossoverWellington Management
Clearbox is a data platform that aggregates historical transaction data along with market research such as market landscapes, scopes of work, solicitations, vendor responses, contracts, and pricing.
B2B MarketplacesData & InfrastructureEnterprise SoftwareGovTechSaaSChicago, US
Chris Foreman(CEO / Co-Founder)inAndrew Watkins(COO / Co-Founder)inCameron Koczon(Co-Founder)in
Co-investorsNetwork Ventures
OKY is a mobile app that lets Latin American immigrants in the United States send digital vouchers for groceries, fast food, fuel, bill payments and mobile top-ups to family members across Latin America, redeemable at nearby stores.
ConsumerFintechSaaSMiami, US
VICTOR UNDA(Co-Founder & CEO)ALEJANDRO MIRÓN(Co-Founder & COO)inESTUARDO FIGUEROA(Co-Founder & CCO)inSANTIAGO ROSSI(Co-Founder & CFO)in
Co-investorsInvariantes FundAlumni VenturesCantos VenturesDCMInnovation EndeavorsPrime Movers Lab+1 more
Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.
BiotechDigital HealthDoylestown, US
Chengzao Sun(Founder)inSandeep Somani(Founder)in
Co-investorsForesite CapitalQuan CapitalRA CapitalLAVOrbiMed
Slate Medicines is a clinical-stage biotechnology company.
BiotechMedical DevicesBoston, US
Sara Pacheco(Executive Officer)Neil Buckley(Executive Officer, Director)inGregory Oakes(Chief Executive Officer and Board Director)in
BoardTim Lohoff(Director)Cindy Xiong(Director)inAndrew Levin(Director)
Co-investorsForesite CapitalRA Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.